Nova Eye Medical (EYE) Chart Thread, page-114

I'll restate what I mentioned in an earlier post, not because it will be any comfort to those who bought in in recent weeks in the 26-28 range, but simply to suggest why the CR needed to be done at 21. I felt coming in to the half yearly, that anything below great results would have seen the SP pullback immediately to the 23-25 range. And it could have been the ROW numbers (now we know what they are).

If that had been the case, the discount of the CR seems now minimal. Of course, this is all guesswork and assumptions. So yes, you could say management were a bit deceptive by putting out great US numbers only after the MAC decision, causing the rapid rise to 28, but by doing that, the necessary funds needed for expansion have been achieved at a higher SP than had they not done it (the dilution still happens, but a larger number would have been issued to bring in the same amount of funds ie perhaps @18 again).

I can't see a lot happening in the next few months and as othera have suggested, I think it likely to range in the low 20s for a while now. More testimonials and surgeons on social media / papers published and conferences over the next 6 months may see gradual rerate. Then the annual in Sept will be the one that hopefully really has some positive numbers.

Ok @bar, I'm with you, there is also a chance for a partner finally jumping aboard for 2RT!

Happy to be proven wrong on the above prediction and we see a move through 30 by EOFY.